Real World Evidence: Data Requirements, Utilization, and Presentation
Recorded December 1, 2017 | On-Demand Webinar
Capturing Postmarket Benefits in Device Compliance and Enforcement
Update Magazine | November/December 2017
Those Involved in Compound Pharmaceuticals Beware: Law Enforcement Is Focused on You
Update Magazine | November/December 2017
Kid Tested, FDA Approved: Examining Pediatric Drug Testing
Food and Drug Law Journal | Volume 72 | Number 4
Get Real: Organic Marketing Under USDA’s Proposed Promotion & Research Agreement
Food and Drug Law Journal | Volume 72 | Number 4
What Happens When FDA Delays a Rule? Menu Labeling as a Case Study
Update Magazine | November/December 2017
When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA GalleryWhen the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA
Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Publications, Volume 72.4
When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA
Food and Drug Law Journal | Volume 72 | Number 4
The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls GalleryThe Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls
Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update November/December 2017
The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls
Update Magazine | September/October 2017
Brand Name Preemption: The New Frontier In Pharmaceutical Product Liability Litigation
Food and Drug Law Journal | Volume 72 | Number 4
The Value of FDA Pre-Submission Meetings & Enhancements under PDUFA VI
Update Magazine | November/December 2017
